Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 2, pp. 392-402
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 195
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 90
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 83
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio, et al.
European Journal of Cancer (2022) Vol. 175, pp. 204-213
Open Access | Times Cited: 74
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice
Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research (2022) Vol. 52, Iss. 9, pp. 773-783
Open Access | Times Cited: 56
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research (2022) Vol. 52, Iss. 7, pp. 630-640
Closed Access | Times Cited: 44
Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience
Anand V. Kulkarni, Vamsi Krishna, Karan Kumar, et al.
Journal of Clinical and Experimental Hepatology (2023) Vol. 13, Iss. 4, pp. 618-623
Open Access | Times Cited: 31
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Anand V. Kulkarni, Harsh Vardhan Tevethia, Karan Kumar, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102179-102179
Open Access | Times Cited: 26
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
Machiko Kai, Hayato Hikita, Maesaka Kazuki, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0294590-e0294590
Open Access | Times Cited: 9
Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers
Vera Himmelsbach, Matthias Pinter, Bernhard Scheiner, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1722-1722
Open Access | Times Cited: 38
Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Medicine (2022) Vol. 12, Iss. 1, pp. 325-334
Open Access | Times Cited: 37
Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
Young Eun Chon, Jaekyung Cheon, Hyeyeong Kim, et al.
Cancer Medicine (2022) Vol. 12, Iss. 3, pp. 2731-2738
Open Access | Times Cited: 31
The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Shigeo Shimose, Hideki Iwamoto, Tomotake Shirono, et al.
Cancer Medicine (2023) Vol. 12, Iss. 11, pp. 12325-12335
Open Access | Times Cited: 19
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice
Shigeo Shimose, Issei Saeki, Tetsu Tomonari, et al.
Oncology Letters (2024) Vol. 28, Iss. 2
Open Access | Times Cited: 7
A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma.
Bengang Wang, X. Hao, Jinshan Yan, et al.
PubMed (2024) Vol. 12, Iss. 3, pp. 225-243
Closed Access | Times Cited: 7
The current status and future of targeted-immune combination for hepatocellular carcinoma
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis
Makoto Chuma, Haruki Uojima, Nobuhiro Hattori, et al.
Hepatology Research (2021) Vol. 52, Iss. 3, pp. 269-280
Closed Access | Times Cited: 37
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Hepatology Research (2021) Vol. 52, Iss. 3, pp. 308-316
Open Access | Times Cited: 37
Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Wei Teng, Chen‐Chun Lin, Chung‐Wei Su, et al.
Journal of Hepatology (2022) Vol. 77, pp. S373-S373
Closed Access | Times Cited: 26
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Iason Psilopatis, Christos Damaskos, Anna Garmpi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2685-2685
Open Access | Times Cited: 16
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
Timothy J. Brown, Ronac Mamtani, Phyllis A. Gimotty, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 6, pp. 2345-2354
Open Access | Times Cited: 14
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 1, pp. 1-6
Open Access | Times Cited: 13
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
Shintaro Takaki, Masayuki Kurosaki, Nami Mori, et al.
Investigational New Drugs (2023) Vol. 41, Iss. 2, pp. 340-349
Closed Access | Times Cited: 12
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
PLoS ONE (2023) Vol. 18, Iss. 2, pp. e0281459-e0281459
Open Access | Times Cited: 11
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Reports (2024) Vol. 7, Iss. 4
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top